Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 272

Sort by

Sort Order Select

Journal Articles

Iron-Chelating Potential of Novel Phytochemicals in Poplar and Cedar Trees

Sarah Lane, BSc, Juergen Ehlting, MSc, PhD, Patrick B Walter, MSc, PhD

Blood (2019) 134 (Supplement_1): 4806.

https://doi.org/10.1182/blood-2019-127259

Published: 2019

Journal Articles

Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All- Trans retinoic Acid (ATRA) through the Transcription Factor CREB

Blood (2019) 134 (Supplement_1): 1692.

https://doi.org/10.1182/blood-2019-128573

Published: 2019

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

Evaluation of Minnelide As a Potential Therapeutic Agent for Preventing the Relapse of AML

Pooja Roy, MBBS, Bhuwan Giri, MD, Vanessa Tonin Garrido, PhD, Dujon Brandon Edwards, Justin M. Watts, MD, Sulagna Banerjee, PhD, Vikas Dudeja, PhD, Sundaram Ramakrishnan, PhD, Ashok Saluja, PhD

Blood (2019) 134 (Supplement_1): 5159.

https://doi.org/10.1182/blood-2019-123567

Published: 2019

Journal Articles

This Is a Title in Title Case: A Combination of Low-Dose Decitabine and Chidamide Resulted in Synergistic Effects on the Proliferation and Apoptosis of Human Myeloid Leukemia Cell Lines

Fangfang Xu, PhD, Honggang Guo, MD, Mingyue Shi, MD, Siwei Liu, MD, Min Wei, MD, Kai Sun, MD, Yuqing Chen, MD

Blood (2019) 134 (Supplement_1): 5160.

https://doi.org/10.1182/blood-2019-128663

Published: 2019

Journal Articles

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Kensuke Kayamori, Cheng Zhong, Daisuke Shinoda, MD, Shuhei Koide, PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Naoya Mimura, MD PhD, Ryoji Ito, Kaoru Tohyama, MD PhD, William Lennox, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Emiko Sakaida, MD PhD, Koutaro Yokote, MD PhD, Atsushi Iwama, MD PhD

Blood (2019) 134 (Supplement_1): 5407.

https://doi.org/10.1182/blood-2019-125200

Published: 2019

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

Journal Articles

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

Metis Hasipek, PhD, Yihong Guan, PhD, Dale Grabowski, BS, Jaroslaw P. Maciejewski, MD PhD, Hetty E. Carraway, MD MBA, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 2553.

https://doi.org/10.1182/blood-2019-130475

Published: 2019

Journal Articles

Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Anneke D. van Dijk, BS, Peter P. Ruvolo, PhD, Fieke W Hoff, BSc, Yihua Qiu, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Anders E. Kolb, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, Eveline S. de Bont, MD PhD, Sophia W.M. Bruggeman, PhD, Terzah M Horton, MD PhD, Steven M. Kornblau, MD

Blood (2019) 134 (Supplement_1): 2676.

https://doi.org/10.1182/blood-2019-128579

Published: 2019

Journal Articles

Human and Pathogen Derived Ndpks Act As Novel Damps and PAMPs to Drive Leukemia Cell Survival and Progression through Signaling Via the TLR4-Mediated Alternative NLRP3 Inflammasome Pathway

Sandro Trova, PhD, Matthew Fenton, MBChB, Bhavini Chauhan, BSc, Avani Puri, Santosh Lomada, BSc, PhD, Alexandra Adams, Thomas Wieland, BSc, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Farhat Latif Khanim, PhD, Chistopher M Bunce, BSc, Fei Lin, MBChB

Blood (2019) 134 (Supplement_1): 2684.

https://doi.org/10.1182/blood-2019-131236

Published: 2019

Journal Articles

Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies

Ryo Ishino, Yumi Kawase, MD, Toshio Kitawaki, MD PhD, Naoshi Sugimoto, MD PhD, Maki Oku, MD, Shumpei Uchida, MD, Osamu Imataki, MD PhD, Akihito Matsuoka, MD PhD, Teruhisa Taoka, MD PhD, Kimihiro Kawakami, MD PhD, Tomoki Todo, MD PhD, Akifumi Takaori-Kondo, MD PhD, Norimitsu Kadowaki, MD PhD

Blood (2019) 134 (Supplement_1): 3242.

https://doi.org/10.1182/blood-2019-127754

Published: 2019

Journal Articles

Temporal autoregulation during human PU.1 locus SubTAD formation

Daniel Schuetzmann, Carolin Walter, Boet van Riel, Sabrina Kruse, Thorsten König, Tabea Erdmann, Alexander Tönges, Eric Bindels, Andre Weilemann, Claudia Gebhard, Klaus Wethmar, Chiara Perrod, Julia Minderjahn, Michael Rehli, Ruud Delwel, Georg Lenz, Stefan Gröschel, Martin Dugas, Frank Rosenbauer

Blood (2018) 132 (25): 2643–2655.

https://doi.org/10.1182/blood-2018-02-834721

Published: 2018

Includes: Supplemental data

Journal Articles

Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies

Blood (2018) 132 (Supplement 1): 4050.

https://doi.org/10.1182/blood-2018-99-115359

Published: 2018

Journal Articles

The Histone Demethylase KDM4A Is Required to Sustain H3K9me3/H3K27me3 Epigenetic States and Oncogenesis in MLL-AF9 Acute Myeloid Leukemia

Matthew E Massett, BSc, Niamh Mannion, BSc,PhD, Laura Monaghan, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Sandra Marmiroli, BSc,PhD, Robert M J Liskamp, BSc, PhD, Alison M Michie, BSc, PhD, David Vetrie, BSc, PhD, Xu Huang, BSc, PhD

Blood (2018) 132 (Supplement 1): 3879.

https://doi.org/10.1182/blood-2018-99-111256

Published: 2018

Journal Articles

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Shaneice Renee Mitchell, BS, Nicole Grieselhuber, MD PhD, Yerdanos Asemelash, Matthew Cannon, BA, Shelley Orwick, BS, Pratibha Sharma, PhD, Virginia Goettl, DVM, PhD, Vinay K Puduvalli, MD MBBS, Deepa Sampath, PhD, Alice S. Mims, MD, James S. Blachly, MD, Amy M. Lehman, PhD, Bonnie K. Harrington, DVM, Justin Breitbach, Erkan Baloglu, William Senapedis, PhD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3931.

https://doi.org/10.1182/blood-2018-99-119358

Published: 2018

Journal Articles

Homozygous Loss of a Critical CTCF Recognition Sequence in the HOXA gene Cluster Eliminates CTCF Binding but Does Not Appreciably Reduce HOXA9 expression in NPM1 Mutated AML Cells

Reza Ghasemi, PhD, Struthers B Heidi, David H Spencer, MD PhD

Blood (2018) 132 (Supplement 1): 2613.

https://doi.org/10.1182/blood-2018-99-119000

Published: 2018

Journal Articles

Restriction of HIV-1 Infection in Sickle Cell Disease and Trait

Namita Kumari, PhD, Miguel de Mulder, PhD, Javed Khan, PhD, Asrar Ahmad, PhD, Songping Wang, Hatajai Lassiter, Nathan Smith, Nowah Kokou Apeadoufia Afangbedji, Andrey Ivanov, PhD, Mitsu Shah, Sharmin Diaz, Sohail Rana, MD, Douglas Nixon, PhD, Sergei Nekhai, PhD

Blood (2018) 132 (Supplement 1): 2337.

https://doi.org/10.1182/blood-2018-99-117029

Published: 2018

Journal Articles

A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis

Ashwin Kishtagari, MBBS, Kwok Peng Ng, PhD, Charlotte Jarman, Anand D. Tiwari, PhD, James G Phillips, PhD, Caroline Schuerger, Babal K. Jha, Yogenthiran Saunthararajah, MD

Blood (2018) 132 (Supplement 1): 216.

https://doi.org/10.1182/blood-2018-99-119311

Published: 2018

Journal Articles

The Non-Canonical, R-Loop Regulatory Function of PIWIL4 Maintains Genomic Integrity and Leukemic Potential of AML Cells

Shiva Bamezai, PhD, Naidu Vegi, PhD, Alex Pulikkottil Jose, Julia Müller, BSc., Ingrid Grummt, Chenlin Song, PhD, Konstanze Döhner, MD, Hartmut Döhner, MD, Michaela Feuring-Buske, MD, Vijay Pal Singh Rawat, PhD, Christian Buske, MD

Blood (2018) 132 (Supplement 1): 879.

https://doi.org/10.1182/blood-2018-99-113281

Published: 2018

NARROW

Iron-Chelating Potential of Novel Phytochemicals in Poplar and Cedar Trees

Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All- Trans retinoic Acid (ATRA) through the Transcription Factor CREB

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Evaluation of Minnelide As a Potential Therapeutic Agent for Preventing the Relapse of AML

This Is a Title in Title Case: A Combination of Low-Dose Decitabine and Chidamide Resulted in Synergistic Effects on the Proliferation and Apoptosis of Human Myeloid Leukemia Cell Lines

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Human and Pathogen Derived Ndpks Act As Novel Damps and PAMPs to Drive Leukemia Cell Survival and Progression through Signaling Via the TLR4-Mediated Alternative NLRP3 Inflammasome Pathway

Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies

Temporal autoregulation during human PU.1 locus SubTAD formation

Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies

The Histone Demethylase KDM4A Is Required to Sustain H3K9me3/H3K27me3 Epigenetic States and Oncogenesis in MLL-AF9 Acute Myeloid Leukemia

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Homozygous Loss of a Critical CTCF Recognition Sequence in the HOXA gene Cluster Eliminates CTCF Binding but Does Not Appreciably Reduce HOXA9 expression in NPM1 Mutated AML Cells

Restriction of HIV-1 Infection in Sickle Cell Disease and Trait

A First-in-Class Inhibitor of ISWI-Mediated (ATP-Dependent) Transcription Repression Releases Terminal-Differentiation in AML Cells While Sparing Normal Hematopoiesis

The Non-Canonical, R-Loop Regulatory Function of PIWIL4 Maintains Genomic Integrity and Leukemic Potential of AML Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only